Marta Batus to Antineoplastic Agents
This is a "connection" page, showing publications Marta Batus has written about Antineoplastic Agents.
Connection Strength
1.825
-
Marta Batus on the New Direct-to-Consumer Advertising for Nivolumab, and Its Impact on Oncology Practice. Oncology (Williston Park). 2016 Jun; 30(6):506, 523.
Score: 0.459
-
Future directions for pediatric and young adult bone sarcoma. Curr Probl Cancer. 2013 Jul-Aug; 37(4):225-35.
Score: 0.375
-
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol. 2013 Jun; 14(3):179-94.
Score: 0.373
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.310
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
Score: 0.087
-
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
Score: 0.084
-
Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib. Am Surg. 2010 Aug; 76(8):E110-2.
Score: 0.077
-
Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr; 46(4):397-405.
Score: 0.061